NCT03294694 2025-05-31
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
Clinical Trials
8 trialsNCT05384119 2025-02-21
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Tvardi Therapeutics, Incorporated
Phase 1 Terminated
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04657679 2024-11-26
LEANORA
Georgetown University
Phase 4 Terminated
NCT02734615 2022-08-01
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Novartis
Phase 1 Terminated
NCT03905343 2021-06-16
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
Swiss Cancer Institute
Phase 3 Terminated
NCT03050398 2020-05-28
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Novartis
Phase 3 Terminated
NCT01919229 2016-01-01
MONALEESA-1
Novartis
Phase 2 Terminated